{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:20:34Z","timestamp":1793780434051,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":49,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtho.2023.03.008","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T01:00:43Z","timestamp":1680051643000},"page":"755-768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-1872","authenticated-orcid":false,"given":"Tamta","family":"Makharadze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Gogishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Melkadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Baramidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davit","family":"Giorgadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Penkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Laktionov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia","family":"Nemsadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Nechaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Rozhkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Kalinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manika","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben G.W.","family":"Quek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Seebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Rietschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.jtho.2023.03.008_bib1","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions","volume":"24","author":"Xia","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2023.03.008_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2023.03.008_bib3","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2023.03.008_bib6","author":"Sanofi-aventis Canada"},{"key":"10.1016\/j.jtho.2023.03.008_bib7","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology: non small cell lung cancer, version 3. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed February 28, 2023."},{"key":"10.1016\/j.jtho.2023.03.008_bib8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 \u226550%: a randomised controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2023.03.008_bib13","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.03.008_bib16","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib17","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib18","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A\u00a0randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib19","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.03.008_bib20","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jtho.2023.03.008_bib21","doi-asserted-by":"crossref","first-page":"S748","DOI":"10.1016\/S1556-0864(21)01939-0","article-title":"97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407","volume":"16","author":"Robinson","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.03.008_bib24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.03.008_bib25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib26","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.03.008_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/2229-3485.179436","article-title":"Common pitfalls in statistical analysis: the perils of multiple testing","volume":"7","author":"Ranganathan","year":"2016","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.jtho.2023.03.008_bib29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.03.008_bib31","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"}],"updated-by":[{"DOI":"10.1016\/j.jtho.2023.07.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000}}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423001855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423001855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T19:35:52Z","timestamp":1740598552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423001855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1556086423001855"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.03.008","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}